Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorios Farmaceuticos RoviLABFF 99 Shiller PE Ratio is 17.63 as of Aug. 25, 2026, which is 59% below its 10-year median of 43.48. GuruFocus rates LABFF with a GF Score™ of 99/100 and a GF Value™ of $85.89 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 528 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 52.46% on this metric.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Shiller PE Ratio or its related term are showing as below:
LABFF'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 22.28 Med: 43.48 Max: 105.81
Current: 24.56
During the past years, Laboratorios Farmaceuticos Rovi's highest Shiller PE Ratio was 105.81. The lowest was 22.28. And the median was 43.48.
LABFF's Shiller PE Ratio is ranked better than 52.46% of 528
companies
in the Drug Manufacturers industry
Industry Median: 25.805
vs LABFF: 24.56
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Laboratorios Farmaceuticos Rovi's adjusted earnings per share data for the three months ended in Jun. 2026 was $1.689. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $3.81 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Laboratorios Farmaceuticos Rovi (OTCPK:LABFF) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Laboratorios Farmaceuticos Rovi Shiller PE Ratio Related Terms
Laboratorios Farmaceuticos Rovi Shiller PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi Shiller PE Ratio Chart
LABFF vs ZTS, UTHR, VTRS: Shiller PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Shiller PE Ratio falls into.
Laboratorios Farmaceuticos Rovi Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Laboratorios Farmaceuticos Rovi (LABFF) has a Shiller PE Ratio of 17.63 as of Aug. 25, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 59% below median its historical median of 43.48. Over the past decade, Laboratorios Farmaceuticos Rovi's Shiller PE Ratio has ranged from 22.28 to 105.81. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #251 out of 528 companies in the Drug Manufacturers industry, placing it in the top 47.5%.
Is Laboratorios Farmaceuticos Rovi's Shiller PE Ratio too high?
Laboratorios Farmaceuticos Rovi's current Shiller PE Ratio of 17.63 is 59% below median its 10-year median of 43.48. Over the past 10 years, this metric has ranged from a low of 22.28 to a high of 105.81. The Drug Manufacturers industry median Shiller PE Ratio is 25.81. Laboratorios Farmaceuticos Rovi's value of 17.63 is 31.7% below this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #251 out of 528 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Shiller PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #251 out of 528 companies for Shiller PE Ratio. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median Shiller PE Ratio is 25.81. Laboratorios Farmaceuticos Rovi's value of 17.63 is 31.7% below this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Shiller PE Ratio has ranged from 22.28 to 105.81 over the past decade. While the company's 10-year median is 43.48 vs. the industry median of 25.81, Laboratorios Farmaceuticos Rovi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.81, based on 528 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Shiller PE Ratio of 17.63 is 31.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Shiller PE Ratio is 17.63, which is 59% below median its own 10-year median of 43.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (LABFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $85.89, compared to a current price of $67.17 — trading 21.8% below its estimated fair value. The current Shiller PE Ratio is 17.63, which is 59% below median its 10-year median of 43.48 and 31.7% below the Drug Manufacturers industry median of 25.81. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Shiller PE Ratio is 17.63 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be undervalued.
The current stock price of $67.17 is trading 21.8% below its estimated GF Value™ of $85.89.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Undervalued.
Key valuation signals for LABFF:
Shiller PE Ratio: 17.63 (59% below median its 10-year median of 43.48)
GF Value™: $85.89 vs. price of $67.17 (21.8% below fair value)
Industry Position: 31.7% below the Drug Manufacturers median (#251 of 528)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
99GF Score
Get the complete analysis for LABFF
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
